Executive Parag Mallick receives 280,000 stock options at Nautilus (NAUT)

Rhea-AI Filing Summary

Mallick Parag reported acquisition or exercise transactions in this Form 4 filing.

Nautilus Biotechnology, Inc. reported that Chief Scientist and 10% owner Parag Mallick was granted stock options covering 280,000 shares of common stock. These options were awarded on March 2, 2026 and are structured as a long-term equity incentive.

The grant vests over time, subject to Mallick’s continued service to the company. Twenty-five percent of the options vest on the one-year anniversary of the January 1, 2026 vesting commencement date, with the remaining options vesting in equal monthly installments over the following thirty-six months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mallick Parag

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientist

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	03/02/2026		A		280,000		(1)	03/02/2036	Common Stock	280,000	$0	280,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Remarks:

	/s/ Mathew B. Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nautilus Biotechnology (NAUT) report for Parag Mallick?

Nautilus Biotechnology reported that Chief Scientist and 10% owner Parag Mallick received a grant of stock options for 280,000 shares. The award is a derivative security and represents a long-term equity incentive tied to his continued service with the company.

How many stock options did Parag Mallick acquire in the latest NAUT Form 4?

Parag Mallick acquired stock options to purchase 280,000 shares of Nautilus Biotechnology common stock. This entire amount was granted on March 2, 2026, and reflects a single equity award reported as an acquisition on the Form 4 filing.

What is the vesting schedule for Parag Mallick’s 280,000 NAUT stock options?

The 280,000 options vest based on continued service. Twenty-five percent vest on the one-year anniversary of the January 1, 2026 vesting commencement date, and one thirty-sixth of the remaining options vests monthly thereafter on the same calendar day.

What conditions apply to the vesting of Parag Mallick’s Nautilus Biotechnology options?

Vesting is conditioned on Mallick maintaining continuous status as a “Service Provider” under Nautilus Biotechnology’s 2021 Equity Incentive Plan. If he remains in this role, the options follow the specified one-year cliff and subsequent monthly vesting schedule from the January 1, 2026 commencement date.

Is Parag Mallick’s Form 4 transaction a purchase or an equity award from NAUT?

The transaction is an equity award, not an open-market share purchase. It is reported with code “A” as a grant or award acquisition of stock options, reflecting compensation granted by Nautilus Biotechnology rather than shares bought on a public market.